Stage 4, or metastatic, breast cancer means the cancer has spread beyond the breast and nearby lymph nodes to distant organs, most often the bones, liver, lungs or brain. It is not considered curable for most women, but it is increasingly treatable, and for many it has become a long-term condition managed through a sequence of treatments, each chosen as the cancer changes. The treatments available in 2026 are far more effective than those of even five years ago. This article explains how stage 4 breast cancer is approached, the tests that open the most options, and the newest advances.
Subtype Decides Everything
Stage 4 breast cancer is not one disease. Treatment depends first on which of three main types it is:
Hormone receptor-positive, HER2-negative, the most common type, is usually treated first with hormone therapy plus a CDK4/6 inhibitor, followed by newer oral hormone drugs and targeted drugs as resistance develops. See hormone receptor-positive breast cancer.
HER2-positive is treated with HER2-targeted drugs, and in 2025 a new first-line combination extended median progression-free survival to more than three years. See HER2-positive breast cancer.
Triple-negative is treated with immunotherapy when PD-L1-positive and, increasingly, with antibody-drug conjugates, one of which became the first first-line treatment to improve overall survival for women who cannot receive immunotherapy. See triple-negative breast cancer.
The Tests That Open the Most Options
A biopsy of a metastasis. Hormone receptor and HER2 status can change between the original tumor and the metastases. When it is safe to do, biopsying a metastasis confirms what the cancer is now.
HER2-low status. Many cancers once called HER2-negative carry low levels of HER2 that qualify them for trastuzumab deruxtecan.
Tumor sequencing. Mutations in PIK3CA, AKT1, PTEN and ESR1 each have specific drugs. See tumor DNA and RNA sequencing.
Inherited BRCA testing opens the door to PARP inhibitors.
PD-L1 decides immunotherapy in triple-negative disease.
Repeated blood tests. ESR1 mutations and other resistance changes appear in the blood as treatment goes on. See ctDNA liquid biopsy.
Should the Breast Tumor Be Removed?
For women diagnosed with stage 4 disease at the start, a common question is whether surgery on the breast tumor helps. The trials disagree. In the American ECOG-ACRIN E2108 trial, early surgery and radiation of the breast tumor did not improve overall survival.1 In the Turkish MF07-01 trial, women who had the breast tumor removed lived longer at long-term follow-up, with the clearest benefit in hormone receptor-positive disease, younger women and those with bone-only metastases.2 The decision is individual and depends on the extent of disease and how it responds to systemic treatment.
Bone and Brain Metastases
Bone. The bones are the most common site of spread. Bone-strengthening drugs such as zoledronic acid and denosumab reduce fractures and bone pain. Women with bone-only disease often live for many years.
Brain. Brain metastases are more common in HER2-positive and triple-negative disease. Several newer drugs cross into the brain, including tucatinib and trastuzumab deruxtecan in HER2-positive disease, and stereotactic radiosurgery treats individual brain lesions precisely.
Monitoring With Circulating Tumor Cells
Metastatic breast cancer is where circulating tumor cell testing began. A landmark 2004 study in the New England Journal of Medicine showed that women with five or more circulating tumor cells in a standard blood sample had shorter survival than those with fewer.3 In the French STIC CTC trial, using the circulating tumor cell count to choose between hormone therapy and chemotherapy as first treatment for hormone receptor-positive metastatic disease was as effective as the clinician’s choice, and when the count was high but the clinician had chosen hormone therapy, chemotherapy did better.4 See our article on circulating tumor cell testing.
When Treatment Stops Working
In stage 4 breast cancer, each treatment eventually stops working, and the next one is chosen based on how the cancer has changed. Re-testing, molecular tumor board review, functional testing and clinical trials all matter at this point. Our guide to what to do when chemotherapy stops working explains each step.
Integrative Care Alongside Treatment
Nutrition, exercise, fasting around chemotherapy, acupuncture for treatment side effects, and selected therapies such as mistletoe and intravenous vitamin C can support women through years of treatment. Our article on integrative treatment for breast cancer reviews the evidence.
How Cancer Expert MD Helps
Cancer Expert MD provides education and consultation for people with every type and stage of cancer, and specializes in Stage IV and metastatic cancer. A consultation reviews records and test results, identifies testing that could open new options, and explains the treatments and trials available in the United States and abroad. Our companion book, The New Reality of Breast Cancer: The Science of Recovery, is coming soon. Learn more on our book page.
Frequently Asked Questions
What is stage 4 breast cancer?
Breast cancer that has spread to distant organs, most often the bones, liver, lungs or brain. It is also called metastatic breast cancer.
Is stage 4 breast cancer treatable?
Yes. It is not curable for most women, but many live for years with a sequence of treatments, and the options in 2026 are far more effective than those of only a few years ago.
Should the breast tumor be removed in stage 4 breast cancer?
The trials disagree. An American trial found no survival benefit, while a Turkish trial found longer survival, especially in hormone receptor-positive disease and bone-only metastases. The decision is individual.
What tests are important in stage 4 breast cancer?
A biopsy of a metastasis when possible, hormone receptor and HER2 status including HER2-low, tumor sequencing, inherited BRCA testing, PD-L1 in triple-negative disease, and repeated ctDNA blood tests.
About the author. Dr. Silver, MD, graduated from Temple University School of Medicine, trained as an interventional cardiologist, and has practiced medicine for nearly fifty years. A lymphoma survivor of about twenty-five years, he is co-author, with Dr. Lindmeier, DHSc, of The New Reality of Cancer: The Science of Recovery. Read more about Dr. Silver, MD.
Research by Dr. Lindmeier, DHSc, cancer educator and co-author of The New Reality of Cancer.
This article is for general education only and is not individual medical advice. Always consult your own doctor before making any changes to your care.
© 2026 Cancer Expert MD, Dr. Silver, MD, and Dr. Lindmeier, DHSc. All rights reserved. This article draws on the research in The New Reality of Cancer and may not be copied, republished or distributed without written permission.
For more in-depth information on this topic and many others, get our book, The New Reality of Cancer: The Science of Recovery.
More articles on breast cancer and all articles.
References
- Khan SA, Zhao F, Goldstein LJ, et al. Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108). Journal of Clinical Oncology. 2022;40(9):978–987.
- Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Annals of Surgical Oncology. 2018;25(11):3141–3149.
- Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine. 2004;351(8):781–791.
- Bidard FC, Jacot W, Kiavue N, et al. Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: the STIC CTC randomized clinical trial. JAMA Oncology. 2021;7(1):34–41.
This article is for education only. It is not medical advice and does not diagnose or treat any condition. Cancer Expert MD has no financial relationship with any laboratory, drug maker, supplement company, clinic or hospital.